

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Crescenzi, et al.

Serial No. 10/540,449

Filed: June 22, 2005

For: HIV INTEGRASE INHIBITORS

Art Unit: 1615Examiner: Not Yet Assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Samira R. Watson Date 4/20/05

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Kenneth R. Walton

Attorney _____ For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3462

Date: April 20, 2006

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number 10/540,449
 Filing Date June 22, 2005
 First Named Inventor Benedetta Crescenzi
 Group Art Unit 1615
 Examiner Name Not Yet Assigned
 Attorney Docket Number ITR0046YP

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1	6,380,249	B1	Young, et al.	04/30/2002
	2	6,306,891	B1	Selnick, et al.	10/23/2001
	3	6,262,055	B1	Young, et al.	07/17/2001
	4	2003/0055071	A1	Anthony, et al.	03/20/2003
	5	2004/229909	A1	Kiyama, et al.	11/18/2004
	6	2005/0075356	A1	DiFrancesco, et al.	04/07/2005
	7	2005/0025774	A1	Crescenzi, et al.	02/03/2005
	8	2004/106627	A1	Gardelli, et al.	06/03/2004
	9	2005/0119482	A1	Egbertson, et al.	06/02/2005
	10	2004/0110804	A1	Walker, et al.	06/10/2004
	11	2004/0204498	A1	Walker, et al.	10/14/2004
	12	2004/0229892	A1	Naidu, et al.	11/18/2004

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	13	WO	01/00578	A1	Tularik, Inc.	01/04/2001
	14	WO	02/30930	A2	Merck & Co., Inc.	04/18/2002
	15	WO	02/30426	A1	Merck & Co., Inc.	04/18/2002
	16	WO	02/055079	A2	Merck & Co., Inc.	07/18/2002
	17	WO	02/036734	A2	Merck & Co., Inc.	05/10/2002
	18	WO	03/016275	A1	Shionogi & Co., Ltd.	02/27/2003
	19	WO	03/35076	A1	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	05/01/2003
	20	WO	03/35077	A1	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	05/01/2003
	21	WO	03/062204	A1	Merck & Co., Inc.	07/31/2003
	22	WO	01/94351	A1	Vertex Pharmaceuticals, Inc.	12/13/2001

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

STATEMENT BY APPLICANT

COMPLETE IF KNOWN.

Application Number	10/540,449
Filing Date	June 22, 2005
First Named Inventor	Benedetta Crescenzi
Group Art Unit	1615
Examiner Name	Not Yet Assigned
Attorney Docket Number	ITR0046YP

Sheet 2 of 3

[illegible][illegible]Date
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/540,449
Filing Date	June 22, 2005
First Named Inventor	Benedetta Crescenzi
Group Art Unit	1615
Examiner Name	Not Yet Assigned
Attorney Docket Number	ITR0046YP

NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005